PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$864M
1-Year Return
33.7%
This Quarter Return
+19.19%
1 Year Return
+33.7%
3 Year Return
+258.24%
5 Year Return
+878.92%
10 Year Return
–
AUM
$783M
AUM Growth
+$49.2M
(+6.7%)
Cap. Flow
-$26.8M
Cap. Flow
% of AUM
-3.42%
Top 10 Holdings %
Top 10 Hldgs %
34.67%
Holding
106
New
16
Increased
38
Reduced
39
Closed
12
Top Buys
| 1 |
Teleflex
TFX
|
$23.8M |
| 2 |
Keros Therapeutics
KROS
|
$13M |
| 3 |
Stryker
SYK
|
$10.1M |
| 4 |
Viridian Therapeutics
VRDN
|
$9.67M |
| 5 |
Arcus Biosciences
RCUS
|
$9.33M |
Top Sells
| 1 |
United Therapeutics
UTHR
|
$17M |
| 2 |
Elevance Health
ELV
|
$15M |
| 3 |
Humana
HUM
|
$11.2M |
| 4 |
Tenet Healthcare
THC
|
$9.17M |
| 5 |
Boston Scientific
BSX
|
$8.75M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BCYC
26
Bicycle Therapeutics
BCYC
$483M
| $10.1M | 1.29% |
445,396
-89,667
| -17% | -$2.03M |
|
27
Nurix Therapeutics
NRIX
$697M
| $9.86M | 1.26% |
438,971
-35,708
| -8% | -$802K |
|
28
Syndax Pharmaceuticals
SNDX
$1.39B
| $9.78M | 1.25% |
508,283
-92,415
| -15% | -$1.78M |
|
|
29
Viridian Therapeutics
VRDN
$1.52B
| $9.67M | 1.23% |
+425,000
| New | +$9.67M |
|
30
Qiagen
QGEN
$10.2B
| $9.6M | 1.23% |
204,914
-22,846
| -10% | -$1.07M |
|
31
RxSight
RXST
$347M
| $9.11M | 1.16% |
184,320
-112,419
| -38% | -$5.56M |
|
|
SLN
32
Silence Therapeutics
SLN
$247M
| $9.05M | 1.16% |
497,870
+208,029
| +72% | +$3.78M |
|
33
Quest Diagnostics
DGX
$20.1B
| $8.54M | 1.09% |
+55,000
| New | +$8.54M |
|
34
Castle Biosciences
CSTL
$670M
| $8.44M | 1.08% |
296,071
+18,176
| +7% | +$518K |
|
35
Replimune Group
REPL
$454M
| $8.37M | 1.07% |
763,747
+238,747
| +45% | +$2.62M |
|
|
CDMO
36
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $8.19M | 1.05% |
719,965
+98,874
| +16% | +$1.13M |
|
37
Jazz Pharmaceuticals
JAZZ
$7.77B
| $8.05M | 1.03% |
+72,256
| New | +$8.05M |
|
38
Applied Therapeutics
APLT
$67M
| $7.71M | 0.98% |
907,294
-241,013
| -21% | -$2.05M |
|
39
Xenon Pharmaceuticals
XENE
$2.98B
| $7.55M | 0.96% |
191,658
-17,632
| -8% | -$694K |
|
40
Icon
ICLR
$13.7B
| $7.53M | 0.96% |
26,212
-10,844
| -29% | -$3.12M |
|
41
PTC Therapeutics
PTCT
$4.61B
| $7.23M | 0.92% |
+195,000
| New | +$7.23M |
|
42
Alnylam Pharmaceuticals
ALNY
$59.4B
| $7.01M | 0.89% |
+25,485
| New | +$7.01M |
|
43
Amicus Therapeutics
FOLD
$2.47B
| $6.46M | 0.83% |
605,318
+102,855
| +20% | +$1.1M |
|
44
Ultragenyx Pharmaceutical
RARE
$3.01B
| $6.08M | 0.78% |
109,468
+9,468
| +9% | +$526K |
|
45
CVRx
CVRX
$201M
| $6.02M | 0.77% |
682,897
+235,277
| +53% | +$2.07M |
|
46
Sutro Biopharma
STRO
$86.5M
| $5.94M | 0.76% |
1,716,132
-76,608
| -4% | -$265K |
|
47
Axogen
AXGN
$709M
| $5.79M | 0.74% |
+412,888
| New | +$5.79M |
|
48
Arcellx
ACLX
$4B
| $5.55M | 0.71% |
66,492
-90,351
| -58% | -$7.55M |
|
|
PHLT
49
Performant Healthcare, Inc. Common Stock
PHLT
$605M
| $5.39M | 0.69% |
1,440,838
-182,361
| -11% | -$682K |
|
50
LivaNova
LIVN
$3.18B
| $5.34M | 0.68% |
101,729
+16,570
| +19% | +$871K |
|